EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Survivin/ BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma

Ester Benaiges, Victòria Ceperuelo-Mallafré, Sandra Guaita, Elsa Maymó-Masip, Ana Madeira, David Gómez, Victor Hernández, Isabel Vilaseca iD, Carla Merma, Xavier León iD, Ximena Terra, Joan Vendrell und 2 weitere

Head & Neck · 2024

DOI: 10.1002/hed.27651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2024. Verfasst von Ester Benaiges und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain. Hauptthemen laut MEDLINE: Survivin, Radiation Tolerance, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Fundación Científica Asociación Española Contra el Cáncer, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic reprogramming and abnormal glucose metabolism are hallmarks of head and neck squamous cell carcinoma (HNSCC). Certain oncogenes can promote cancer‐related metabolic changes, but understanding their crosstalk in HNSCC biology and treatment is essential for identifying predictive biomarkers and developing target therapies.

Methods

We assessed the value of survivin/BIRC5 as a radioresistance factor potentially modulated by glucose for predicting therapeutic sensitivity and prognosis of HNSCC in a cohort of 32 patients. Additionally, we conducted in vitro experiments to explore the role of survivin/BIRC5 in glucose metabolism concerning radiation response.

Results

Tumoral BIRC5 expression is associated with serum glucose and predicts locoregional disease‐free survival and lower BIRC5 mRNA levels are associated with better outcomes. Upregulation of BIRC5 by radiation depends on glucose levels and provokes a pro‐tumoral and radioresistant phenotype in surviving cells.

Conclusions

Survivin/BIRC5 might be independently associated with the risk of recurrence in patients with HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SurvivinRadiation ToleranceHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckGlucoseHumansMaleFemaleMiddle AgedAgedPrognosisCell Line, TumorDisease-Free SurvivalBiomarkers, TumorCarcinoma, Squamous CellInhibitor of Apoptosis ProteinsAdult

Stichwörter der Autor:innen

HNSCCglucose metabolismradioresistanceradiotherapysurvivin

Substanzen

SurvivinBIRC5 protein, humanGlucoseBiomarkers, TumorInhibitor of Apoptosis Proteins

Autor:innen und Institutionen

  • Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.
  • Grup de Recerca en Diabetis i Malalties Metabòliques Associades (DIAMET), Institut d'Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari Joan XXIII, Tarragona, Spain.
  • CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Departament d'Oncologia, Hospital Universitari Sant Joan, Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
  • Unitat de Recerca en Lípids i Arteriosclerosi (URLA), Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, Reus, Spain.
  • Servei d'Oncologia Radioteràpica, Hospital Universitari Sant Joan, Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.

ORCID-Profile: Isabel Vilaseca, Xavier León, Francesc Xavier Avilés-Jurado, Sonia Fernández-Veledo

Förderung

  • Instituto de Salud Carlos III
  • Fundación Científica Asociación Española Contra el Cáncer
  • Ministerio de Ciencia e Innovación
  • Universitat Rovira i Virgili
  • Ramón y Cajal program
  • Miguel Servet tenue track program
  • Departament de Recerca i Universitats de la Generalitat de Catalunya

Zitieren

APA

Benaiges, E., Ceperuelo-Mallafré, V., Guaita, S., Maymó-Masip, E., Madeira, A., Gómez, D., Hernández, V., Vilaseca, I., Merma, C., León, X., Terra, X., Vendrell, J., Avilés-Jurado, F. X., & Fernández-Veledo, S. (2024). Survivin/ BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma. Head & Neck. https://doi.org/10.1002/hed.27651

Vancouver

Benaiges E, Ceperuelo-Mallafré V, Guaita S, Maymó-Masip E, Madeira A, Gómez D, et al. Survivin/ BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma. Head & Neck. 2024. doi:10.1002/hed.27651

BibTeX
@article{Benaiges2024,
  author = {Benaiges, Ester and Ceperuelo-Mallafré, Victòria and Guaita, Sandra and Maymó-Masip, Elsa and Madeira, Ana and Gómez, David and Hernández, Victor and Vilaseca, Isabel and Merma, Carla and León, Xavier and Terra, Ximena and Vendrell, Joan and Avilés-Jurado, Francesc Xavier and Fernández-Veledo, Sonia},
  title = {Survivin/ BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma},
  journal = {Head & Neck},
  year = {2024},
  doi = {10.1002/hed.27651}
}
Kostenlos starten →